<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00599248</url>
  </required_header>
  <id_info>
    <org_study_id>TGC-03-01</org_study_id>
    <nct_id>NCT00599248</nct_id>
  </id_info>
  <brief_title>Safety Study of TissueGene-C in Degenerative Joint Disease of the Knee</brief_title>
  <acronym>TGC-03-01</acronym>
  <official_title>A Phase 1 Study to Determine the Safety and Biological Activity of Cell-Mediated Gene Therapy Using TissueGene-C in Patients With Degenerative Joint Disease Prior to Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TissueGene, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TissueGene, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to investigate the safety and activity of TissueGene-C injected
      into the knee joint of patients with chronic degenerative joint disease (DJD) who will be
      undergoing total knee replacement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this first human study is to investigate the safety and biological activity of
      intra-articularly applied TissueGene-C in patients with chronic degenerative joint disease
      (DJD) who will be undergoing total knee replacement. In addition, data on joint pain, range
      of motion, and functionality will be obtained in this patient population prior to total knee
      replacement.

      The primary objective of this study is to evaluate the safety and biological activity of
      intra-articularly administered TissueGene-C as evidenced by observation of the injection site
      for irritation or other abnormalities affecting the incidence and severity of adverse events,
      and the changes in physical examination findings and laboratory tests as compared to the
      placebo control.

      The secondary objectives of this study are to:

        1. Evaluate the dose response of the hChonJb#7 cells in grafting at the defect as compared
           to the placebo control.

        2. Evaluate distribution of hChonJb#7 cells out of the injection site.

        3. Evaluate the regeneration of hyaline cartilage as determined by the histological
           analysis of the resected knee tissue.

        4. Evaluate the joint for evidence of tissue overgrowth or transformation.

        5. Evaluate the biological activity of TissueGene-C on joint pain, range of motion and
           functionality as compared to the placebo control
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Summary of Adverse Events</measure>
    <time_frame>Through 28 days post-dosing</time_frame>
    <description>The incidence of observations at the site of administration and the incidence adverse events assessed through 28 days after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Showing Engraftment at the Defect</measure>
    <time_frame>28 Days</time_frame>
    <description>Dose Response of the TG-C in Engrafting at the Defect as Compared to Placebo Control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Distribution of hChonJb#7 Cells Detected Outside of the Injection Site</measure>
    <time_frame>12 Months</time_frame>
    <description>Number of Patients with Distribution of hChonJb#7 Cells Detected Outside of the Injection Site as determined by PCR analysis for vector DNA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Observable Evidence of Cartilage Regeneration</measure>
    <time_frame>Days 0, 3, 7, 11, 28 (prior to surgery), and day 29 (one day post-surgery) following dosing. Follow-up patient monitoring will be performed at 3, 6, 9, and 12 months following dosing</time_frame>
    <description>The evaluation of regeneration of hyaline cartilage as determined by histological analysis of resected knee tissue and observation for engraftment and cartilage production.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Tissue Overgrowth or Transformation in the Knee Joint</measure>
    <time_frame>29</time_frame>
    <description>Visual and histological analysis of knee joint tissues to determine the number of patients with tissue overgrowth or transformation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Improvements in Pain and Function of the Knee Joint</measure>
    <time_frame>28 Days</time_frame>
    <description>Assessment of the number of patients with improvement in pain and function of the knee joint</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TissueGene-C single intraarticular injection of 3x10e6 cells/joint</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TissueGene-C single intraarticular injection of 1x10e7 cells/joint</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TissueGene-C single intraarticular injection of 3x10e7 cells/joint</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control single intraarticular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TissueGene-C</intervention_name>
    <description>TissueGene-C at 3x10e6, 1x10e7 or 3x10e7 cells/joint to be administered by intra-articular injection</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo control (DMEM)</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or Female subjects

          2. Age 18 years and older

          3. In general good health as evidenced by physical examination, normal hematology, serum
             chemistry, and urinalysis screening laboratory results, and a negative history of
             significant organ system disorders. All laboratory values must be within 20% of normal
             ranges.

          4. Patients with Degenerative Joint Disease (DJD) of the knee that is refractory to
             existing drug therapies and who are scheduled for Total Knee Arthroplasty.

          5. Based on Radiographic findings, defect should be more than 2 cm.

          6. Patients providing written informed consent, after the nature of the study, are fully
             explained.

          7. Body Mass Index (BMI) should be between '18.5 - 45.5'. The applied scale is the same
             for both men and women.

          8. Blood Pressure measurements - Systolic Blood Pressure (SBP) should be between
             90-160mm. Hg, and Diastolic Blood Pressure (DBP) between 50-90mm.Hg,

          9. Osteoarthritis confirmed by the Radiographic Criteria of Kellgren and Lawrence

         10. Symptom of pain for more than four (4) consecutive months and intensity greater than
             Grade 4 on the 11-point numeric scale.

        Exclusion Criteria:

          1. Patients with abnormal hematology, serum chemistry, or urinalysis screening laboratory
             results

          2. Patients taking anti-inflammatory medications (prescription or over-the-counter),
             including herbal therapies, within 14 days of baseline visit

          3. Patients with a recent (within 1 year) history of drug abuse and/or a positive urine
             drug/alcohol test at the time of screening

          4. Patients receiving injections to the treated knee within 2 months prior to study entry

          5. Patients who are pregnant or currently breast-feeding children

          6. Patients with systemic, rheumatic, or inflammatory disease of the knee or
             chondrocalcinosis, hemochromatosis, inflammatory arthritis, necrosis of the femoral
             condyle, arthropathy of the knee associated with juxta-articular Paget's disease of
             the femur or tibia, ochronosis, hemophilic arthropathy, infectious arthritis,
             Charcot's knee joint, villonodular synovitis, and synovial chondromatosis.

          7. Patients with ongoing infectious disease, including HIV and hepatitis

          8. Patients with clinically significant cardiovascular, renal, hepatic, endocrine
             disease, cancer, or Type I diabetes

          9. Patients participating in a study of an experimental drug or medical device within 30
             days of study entry.

         10. Positive drug screen at screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Mont, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sinai Hospital of Baltimore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Romness, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Commonwealth Orthopedics, Virginia Hospital Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sinai Hospital of Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Commonwealth Orthopedics</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2008</study_first_submitted>
  <study_first_submitted_qc>January 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2008</study_first_posted>
  <results_first_submitted>May 23, 2016</results_first_submitted>
  <results_first_submitted_qc>May 23, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 30, 2016</results_first_posted>
  <last_update_submitted>June 7, 2017</last_update_submitted>
  <last_update_submitted_qc>June 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarthritis, knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Enrollment and assignment of patients in Arms 2 and 3 (dose escalation to sequentially higher doses) was only performed after completion of review of safety data in the previous Arm (lower dose) by the Independent Data Monitoring Committee</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Active Treatment (TG-C) 1</title>
          <description>TissueGene-C at 3x10e6 cells/joint
TissueGene-C: TissueGene-C at 3x10e6 cells/joint administered by single intra-articular injection</description>
        </group>
        <group group_id="P2">
          <title>Active Treatment (TG-C) 2</title>
          <description>TissueGene-C at 1 x 10e7 cells/joint
TissueGene-C: TissueGene-C at 1x10e7 cells/joint administered by single intra-articular injection</description>
        </group>
        <group group_id="P3">
          <title>Active Treatment (TG-C) 3</title>
          <description>TissueGene-C at 3x10e7 cells/joint
TissueGene-C: TissueGene-C at 3x10e7 cells/joint administered by single intra-articular injection</description>
        </group>
        <group group_id="P4">
          <title>Placebo Control (DMEM)</title>
          <description>Placebo Control (DMEM)
Placebo: Placebo control (DMEM) administered by a single intraarticular injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Adults 18 or older with degenerative joint disease of the knee (confirmed by Kellgren and Lawrence criteria) refractory to existing drug therapies who were scheduled for total knee arthroplasty.</population>
      <group_list>
        <group group_id="B1">
          <title>Active Treatment (TG-C)</title>
          <description>TissueGene-C at 3x10e6, 1x10e7 or, 3x10e7 cells/joint
TissueGene-C: TissueGene-C at 3x10e6, 1x10e7 or 3x10e7 cells/joint to be administered by intra-articular injection</description>
        </group>
        <group group_id="B2">
          <title>Placebo Control (DMEM)</title>
          <description>Placebo control
Placebo: Placebo control (DMEM)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.0" lower_limit="39" upper_limit="67"/>
                    <measurement group_id="B2" value="60.0" lower_limit="36" upper_limit="61"/>
                    <measurement group_id="B3" value="60.5" lower_limit="36" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Summary of Adverse Events</title>
        <description>The incidence of observations at the site of administration and the incidence adverse events assessed through 28 days after treatment.</description>
        <time_frame>Through 28 days post-dosing</time_frame>
        <population>Intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment (TG-C) 1</title>
            <description>TissueGene-C at 3x10e6 cells/joint
TissueGene-C: TissueGene-C at 3x10e6 cells/joint to be administered by a single intra-articular injection</description>
          </group>
          <group group_id="O2">
            <title>Active Treatment (TG-C) 2</title>
            <description>TissueGene-C at 1x10e7 cells/joint
TissueGene-C: TissueGene-C at 1x107 cells/joint to be administered by a single intra-articular injection</description>
          </group>
          <group group_id="O3">
            <title>Active Treatment (TG-C) 3</title>
            <description>TissueGene-C at 3x10e7 cells/joint
TissueGene-C: TissueGene-C at 3x10e7 cells/joint to be administered by a single intra-articular injection</description>
          </group>
          <group group_id="O4">
            <title>Placebo Control (DMEM)</title>
            <description>Placebo control
Placebo: Placebo control (DMEM)</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Adverse Events</title>
          <description>The incidence of observations at the site of administration and the incidence adverse events assessed through 28 days after treatment.</description>
          <population>Intention-to-treat</population>
          <units>Adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Showing Engraftment at the Defect</title>
        <description>Dose Response of the TG-C in Engrafting at the Defect as Compared to Placebo Control</description>
        <time_frame>28 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment (TG-C) 1</title>
            <description>TissueGene-C at 3x10e6 cells/joint
TissueGene-C: TissueGene-C at 3x10e6 cells/joint to be administered by a single intra-articular injection</description>
          </group>
          <group group_id="O2">
            <title>Active Treatment (TG-C) 2</title>
            <description>TissueGene-C at 1x10e7 cells/joint
TissueGene-C: TissueGene-C at 1x10e7 cells/joint to be administered by a single intra-articular injection</description>
          </group>
          <group group_id="O3">
            <title>Active Treatment (TG-C) 3</title>
            <description>TissueGene-C at 3x10e7 cells/joint
TissueGene-C: TissueGene-C at 3x10e7 cells/joint to be administered by a single intra-articular injection</description>
          </group>
          <group group_id="O4">
            <title>Placebo Control (DMEM)</title>
            <description>Placebo control
Placebo: Placebo control (DMEM)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Showing Engraftment at the Defect</title>
          <description>Dose Response of the TG-C in Engrafting at the Defect as Compared to Placebo Control</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Distribution of hChonJb#7 Cells Detected Outside of the Injection Site</title>
        <description>Number of Patients with Distribution of hChonJb#7 Cells Detected Outside of the Injection Site as determined by PCR analysis for vector DNA.</description>
        <time_frame>12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment (TG-C) 1</title>
            <description>TissueGene-C at 3x10e6 cells/joint
TissueGene-C: TissueGene-C at 3x10e6 cells/joint to be administered by a single intra-articular injection</description>
          </group>
          <group group_id="O2">
            <title>Active Treatment (TG-C) 2</title>
            <description>TissueGene-C at 1x10e7 cells/joint
TissueGene-C: TissueGene-C at 1x10e7 cells/joint to be administered by a single intra-articular injection</description>
          </group>
          <group group_id="O3">
            <title>Active Treatment (TG-C) 3</title>
            <description>TissueGene-C at 3x10e7 cells/joint
TissueGene-C: TissueGene-C at 3x10e7 cells/joint to be administered by a single intra-articular injection</description>
          </group>
          <group group_id="O4">
            <title>Placebo Control (DMEM)</title>
            <description>Placebo control
Placebo: Placebo control (DMEM)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Distribution of hChonJb#7 Cells Detected Outside of the Injection Site</title>
          <description>Number of Patients with Distribution of hChonJb#7 Cells Detected Outside of the Injection Site as determined by PCR analysis for vector DNA.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Observable Evidence of Cartilage Regeneration</title>
        <description>The evaluation of regeneration of hyaline cartilage as determined by histological analysis of resected knee tissue and observation for engraftment and cartilage production.</description>
        <time_frame>Days 0, 3, 7, 11, 28 (prior to surgery), and day 29 (one day post-surgery) following dosing. Follow-up patient monitoring will be performed at 3, 6, 9, and 12 months following dosing</time_frame>
        <population>Intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment (TG-C) 1</title>
            <description>TissueGene-C at 3x10e6 cells/joint
TissueGene-C: TissueGene-C at 3x10e6 cells/joint to be administered by a single intra-articular injection</description>
          </group>
          <group group_id="O2">
            <title>Active Treatment (TG-C) 2</title>
            <description>TissueGene-C at 1x10e7 cells/joint
TissueGene-C: TissueGene-C at 1x10e7 cells/joint to be administered by a single intra-articular injection</description>
          </group>
          <group group_id="O3">
            <title>Active Treatment (TG-C) 3</title>
            <description>TissueGene-C at 3x10e7 cells/joint
TissueGene-C: TissueGene-C at 3x10e7 cells/joint to be administered by a single intra-articular injection</description>
          </group>
          <group group_id="O4">
            <title>Placebo Control (DMEM)</title>
            <description>Placebo control
Placebo: Placebo control (DMEM)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Observable Evidence of Cartilage Regeneration</title>
          <description>The evaluation of regeneration of hyaline cartilage as determined by histological analysis of resected knee tissue and observation for engraftment and cartilage production.</description>
          <population>Intention-to-treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Tissue Overgrowth or Transformation in the Knee Joint</title>
        <description>Visual and histological analysis of knee joint tissues to determine the number of patients with tissue overgrowth or transformation</description>
        <time_frame>29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment (TG-C) 1</title>
            <description>TissueGene-C at 3x10e6 cells/joint
TissueGene-C: TissueGene-C at 3x10e6 cells/joint to be administered by a single intra-articular injection</description>
          </group>
          <group group_id="O2">
            <title>Active Treatment (TG-C) 2</title>
            <description>TissueGene-C at 1x10e7 cells/joint
TissueGene-C: TissueGene-C at 1x10e7 cells/joint to be administered by a single intra-articular injection</description>
          </group>
          <group group_id="O3">
            <title>Active Treatment (TG-C) 3</title>
            <description>TissueGene-C at 3x10e7 cells/joint
TissueGene-C: TissueGene-C at 3x10e7 cells/joint to be administered by a single intra-articular injection</description>
          </group>
          <group group_id="O4">
            <title>Placebo Control (DMEM)</title>
            <description>Placebo control
Placebo: Placebo control (DMEM)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Tissue Overgrowth or Transformation in the Knee Joint</title>
          <description>Visual and histological analysis of knee joint tissues to determine the number of patients with tissue overgrowth or transformation</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Improvements in Pain and Function of the Knee Joint</title>
        <description>Assessment of the number of patients with improvement in pain and function of the knee joint</description>
        <time_frame>28 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment (TG-C) 1</title>
            <description>TissueGene-C at 3x10e6 cells/joint
TissueGene-C: TissueGene-C at 3x10e6 cells/joint to be administered by a single intra-articular injection</description>
          </group>
          <group group_id="O2">
            <title>Active Treatment (TG-C) 2</title>
            <description>TissueGene-C at 1x10e7 cells/joint
TissueGene-C: TissueGene-C at 1x10e7 cells/joint to be administered by a single intra-articular injection</description>
          </group>
          <group group_id="O3">
            <title>Active Treatment (TG-C) 3</title>
            <description>TissueGene-C at 3x10e7 cells/joint
TissueGene-C: TissueGene-C at 3x10e7 cells/joint to be administered by a single intra-articular injection</description>
          </group>
          <group group_id="O4">
            <title>Placebo Control (DMEM)</title>
            <description>Placebo control
Placebo: Placebo control (DMEM)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Improvements in Pain and Function of the Knee Joint</title>
          <description>Assessment of the number of patients with improvement in pain and function of the knee joint</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 Year</time_frame>
      <desc>Treatment emergent adverse events</desc>
      <group_list>
        <group group_id="E1">
          <title>Active Treatment (TG-C)</title>
          <description>TissueGene-C at 3x10e6, 1x10e7 or, 3x10e7 cells/joint
TissueGene-C: TissueGene-C at 3x10e6, 1x10e7 or 3x10e7 cells/joint to be administered by intra-articular injection</description>
        </group>
        <group group_id="E2">
          <title>Placebo Control (DMEM)</title>
          <description>Placebo control
Placebo: Placebo control (DMEM)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated PTT prolonged</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>PT Prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Blood test abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Lower extremity mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis allgergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis generalized</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was designed a a preliminary assessment of safety in a limited population (12 subjects: 9 active 3 placebo) therefore statistics are presented descriptively.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>R. Ogden Copeland</name_or_title>
      <organization>TissueGene, Inc</organization>
      <phone>(301) 921-6000 ext 122</phone>
      <email>ocopeland@tissuegene.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

